{"id":167415,"date":"2010-01-11T17:09:50","date_gmt":"2010-01-11T22:09:50","guid":{"rendered":"tag:typepad.com,2003:post-6a00d8341c89dd53ef012876c76196970c"},"modified":"2010-01-12T17:28:58","modified_gmt":"2010-01-12T22:28:58","slug":"ge-healthcare-seemingly-tries-to-intimidate-and-silence-a-critic-of-its-omniscan-product","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/167415","title":{"rendered":"GE Healthcare Seemingly Tries To Intimidate And Silence A Critic Of Its Omniscan Product"},"content":{"rendered":"<div xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<p><strong><span style=\"FONT-SIZE: 14px; FONT-FAMILY: \"><span style=\"FONT-SIZE: 15px; FONT-FAMILY: \"><span style=\"FONT-SIZE: 16px; FONT-FAMILY: \">Drug Company Files Libel Lawsuit In UK Against Prominent Danish Radiologist Henrik Thomsen<\/span><\/span><\/span><\/strong><\/p>\n<p><span style=\"FONT-SIZE: 16px; FONT-FAMILY: Verdana\"><span style=\"FONT-SIZE: 16px; FONT-FAMILY: Verdana\"><span style=\"FONT-SIZE: 16px; FONT-FAMILY: Verdana\"><span style=\"FONT-SIZE: 16px; FONT-FAMILY: Verdana\"><font size=\"2\"><strong>(Posted by Tom Lamb at <a href=\"http:\/\/www.drug-injury.com\/\" ><span style=\"COLOR: #003366\"><font size=\"2\"><strong>DrugInjuryWatch.com<\/strong><\/font><\/span><\/a><font size=\"2\"><strong>)<\/strong><\/font><\/strong><\/font><\/span><\/span><\/span><\/span><\/p>\n<p><a href=\"http:\/\/www.timesonline.co.uk\/tol\/news\/\" ><em>The Sunday Times<\/em> (UK)<\/a>\u00a0recently ran a story that demonstrates how Britain&#8217;s libel laws are possibly being used by GE Healthcare to intimidate a prominent Danish radiologist, Henrik Thomsen, M.D.,\u00a0into stopping his criticism of its <a href=\"http:\/\/www.drug-injury.com\/drug_injury\/omniscan\/\" >Omniscan product, which has been in the news recently<\/a>.<\/p>\n<p>In the December 20, 2009 edition of <em>The Sunday Times<\/em> (UK) one found this descriptively titled article: <a href=\"http:\/\/business.timesonline.co.uk\/tol\/business\/law\/article6962816.ece\" >&#8220;Libel gag on talk of &#8216;medical hurricane&#8217; &#8212; A healthcare firm is seeking to silence a Danish academic from expressing doubts about one of its products by using England\u2019s draconian libel laws&#8221;<\/a>.<\/p>\n<p>Another version of this article, <a href=\"http:\/\/www.propublica.org\/feature\/ges-omniscan-lawsuit-ratchets-up-volume-in-british-libel-debate-1219\" >&#8220;GE Suit Hushes Scientist Critical of Omniscan&#8221;<\/a>, was published online at <a href=\"http:\/\/www.propublica.org\"><em>ProPublica<\/em><\/a>, which is a US-based independent, non-profit newsroom that produces investigative journalism in the public interest.\u00a0 Therein, reporters\u00a0 Jeff Gerth, of <em>ProPublica<\/em>, and Jon Ungoed-Thomas, of <em>The Sunday Times <\/em>(UK), tell us about this war being waged by GE Healthcare in the UK court system against Dr. Thomasen, a well-respected medical doctor who is not even a resident of Great Britain.\u00a0 From this <em>ProPublica<\/em> version of the article:<\/p>\n<blockquote dir=\"ltr\">\n<p>Two years ago in a conference room in the Randolph hotel in Oxford, England, Henrik Thomsen gave his inside account of a medical &#8220;nightmare.&#8221; In a presentation to about 30 colleagues, Thomsen, one of Europe&#8217;s leading radiologists, revealed how patients treated at his Copenhagen University hospital had subsequently contracted a rare and potentially fatal disease&#8230;.<\/p>\n<p>Thomsen, however, now refuses to speak anywhere in England on the possible risks of Omniscan. The reason is that he faces another kind of storm: GE Healthcare is suing him for libel in the UK High Court.<\/p>\n<p>The company claims his presentation in Oxford \u2014 entitled &#8220;Management Aspects of NSF&#8221; \u2014 was highly defamatory. GE has already racked up costs of more than \u00a3380,000 (about $615,000) pursuing the respected academic, who has authored or co-authored nearly 400 papers and delivered countless presentations to his peers. Thomsen will have to pay GE&#8217;s costs if he loses the case.<\/p>\n<\/blockquote>\n<p>Further, this online article at <em>ProPublica\u00a0<\/em>about GE Healthcare, Omniscan, and Dr. Thomasen includes several background items in the sidebar of that web page:<\/p>\n<ul>\n<li>GE Omniscan Investigation\n<li>About GE Healthcare\n<li>Nephrogenic Systemic Fibrosis\n<li>Omniscan and NSF\n<li>How Three Hospitals Handled Omniscan\n<li>Documents <\/li>\n<\/li>\n<\/li>\n<\/li>\n<\/li>\n<\/li>\n<\/ul>\n<p>The <em>ProPublica <\/em>site also has a 135 PDF presentation, <a href=\"http:\/\/documents.propublica.org\/ge-v-thomsen-a-british-libel-case#p=1\" >&#8220;GE v. Thomsen: A British Libel Case&#8221;<\/a>, which contains the following related documents:<\/p>\n<ul>\n<li>Slides from Thomasen&#8217;s 2006 presentation on Omniscan cases at Copenhagen University Hospital\n<li>GE&#8217;s legal filing accusing Thomsen of libel\n<li>Thomasen&#8217;s response to GE&#8217;s accusation\n<li>GE&#8217;s response to Thomasen&#8217;s defense <\/li>\n<\/li>\n<\/li>\n<\/li>\n<\/ul>\n<p>We are anxious to hear reactions from our readers about this apparent &#8220;beat-down&#8221; tactic by Big Pharma.\u00a0 Please let us know what you think by submitting a Comment, below.<\/p>\n<p>______________________________________________________________________________<\/p>\n<p><a href=\"http:\/\/www.druginjurylaw.com\/\" ><strong><span style=\"FONT-SIZE: 14px; FONT-FAMILY: \"><font color=\"#810081\">DrugInjuryLaw.com<\/font><\/span><\/strong><\/a>: <span style=\"COLOR: #ff0000; FONT-FAMILY: \"><span style=\"COLOR: #80c0ff; FONT-FAMILY: \"><span style=\"COLOR: #800000; FONT-FAMILY: \"><span style=\"COLOR: #302449; FONT-FAMILY: \"><strong>Legal Information And News About Prescription Drug Side Effects<\/strong><\/span><\/span><\/span><\/span><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F10%2Fdrug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F11%2Fbyetta-exenatide-kidney-function-renal-failure-fda-dear-doctor-label-change-october-2009.html\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F11%2Faranesp-darbepoetin-alfa-associated-with-heightened-stroke-risk-amgen-treat-study-nejm-october.html\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F11%2Fanemia-drugs-aranesp-procrit-blood-clots-study-esas-thromboembolism-dvt-pe-stroke.html\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F11%2Fconsumers-unions-safe-patient-project-forum-webcast-to-err-is-human-to-delay-is-deadly.html\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F11%2Fdrug-industry-document-archive-dida-ucsf-november-2009-additions.html\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F11%2Fyaz-drsp-safety-inas-oc-study-venous-thrombosis-pulmonary-embolism-myocardial-infarction-cerebrovascular-accidents.html\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F11%2Fmeridia-stroke-heart-attack-cardiac-death-fda-sibutramine-early-communication.html\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F12%2Ffosamax-onj-side-effect-osteonecrosis-jaw-bisphosphonates-medical-journal-articles-november-2009.html\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F12%2Fpulmonary-embolism-drug-reactions-yaz-yasmin-ocella-nuvaring-ortho-evra-diagnostic-errors.html\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F12%2Fvoltaren-diclofenac-linked-liver-failure-drug-induced-liver-injury-december-2009-fda.html\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F12%2Ffosamax-femur-fractures-femoral-stress-bisphosphonates-drug-injury.html\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F12%2Fdigitek-federal-court-mdl-judge-sets-joint-daubert-hearing-nj-pa-tx-nj-consolidations.html\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F12%2Fzetia-vytorin-cancer-side-effect-safety-study-update-fda-december-2009.html\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F12%2Ffda-gao-report-december-2009-drug-safety-monitoring-agency-changes.html\" type=\"text\/javascript\"><\/script><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2010%2F01%2Ffda-introduces-a-new-web-site-intended-to-give-the-public-more-insight-about-agencys-work.html\" type=\"text\/javascript\"><\/script><\/div>\n<div class=\"feedflare\">\n<a href=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?a=IkVrMAGXwH0:8haTC6eAt60:yIl2AUoC8zA\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?d=yIl2AUoC8zA\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?a=IkVrMAGXwH0:8haTC6eAt60:F7zBnMyn0Lo\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?i=IkVrMAGXwH0:8haTC6eAt60:F7zBnMyn0Lo\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?a=IkVrMAGXwH0:8haTC6eAt60:V_sGLiPBpWU\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?i=IkVrMAGXwH0:8haTC6eAt60:V_sGLiPBpWU\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?a=IkVrMAGXwH0:8haTC6eAt60:l6gmwiTKsz0\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?d=l6gmwiTKsz0\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?a=IkVrMAGXwH0:8haTC6eAt60:gIN9vFwOqvQ\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?i=IkVrMAGXwH0:8haTC6eAt60:gIN9vFwOqvQ\" border=\"0\"><\/img><\/a>\n<\/div>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/drug-injury-watch\/~4\/IkVrMAGXwH0\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Drug Company Files Libel Lawsuit In UK Against Prominent Danish Radiologist Henrik Thomsen (Posted by Tom Lamb at DrugInjuryWatch.com) The Sunday Times (UK)\u00a0recently ran a story that demonstrates how Britain&#8217;s libel laws are possibly being used by GE Healthcare to intimidate a prominent Danish radiologist, Henrik Thomsen, M.D.,\u00a0into stopping his criticism of its Omniscan product, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-167415","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/167415","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=167415"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/167415\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=167415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=167415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=167415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}